{"url_path":"/sec/rani/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1856725/0001193125-26-226703-index.html","accession_number":"0001193125-26-226703","cik":"0001856725","ticker":"RANI","issuer_name":"Rani Therapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1856725/0001193125-26-226703-index.html","primary_entity_key":"0001856725","primary_entity_name":"Rani Therapeutics Holdings, Inc."},"word_count":88,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds\n\nIn January 2026, we issued 2,099,844 shares of our Class A common stock to funds affiliated with Avenue Venture Opportunities Fund, L.P (the “Lender”) upon exercise by the Lender of the Pre-Funded Warrants issued in the Private Placement in October 2025. The Pre-Funded Warrants were exercised on a cashless basis in accordance with their terms, resulting in no cash proceeds to us. The issuance was exempt from registration under Section 3(a)(9) of the Securities Act of 1933."}